Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Viracta Therapeutics announced participation in the 20th Annual Needham Virtual Healthcare Conference from April 12-15, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Viracta Therapeutics announced participation in the 20th Annual Needham Virtual Healthcare Conference from April 12-15, 2021. The Company will present on April 14, 2021, at 3:45 PM ET, focusing on its precision oncology efforts targeting virus-associated malignancies. Viracta's investigational drug, nanatinostat, is in a Phase 2 trial for EBV-positive lymphoma, combined with valganciclovir, and is exploring applications for other EBV-related cancers. For more details, visit www.viracta.com.
Details
News Market Reaction – VIRX
The recorded move for VIRX in the trading session of this news was -1.58%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, April 8, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the 20th Annual Needham Virtual Healthcare Conference taking place April 12-15, 2021. The Company will also participate in one-on-one investor meetings at the conference.
Details on the presentation can be found below.
Date: | Wednesday, April 14, 2021 |
Time: | 3:45 PM ET |
Format: | Corporate presentation |
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
For additional information please visit www.viracta.com.
Investor Relations Contact: | Company Contact: |
Joyce Allaire | Dan Chevallard |
LifeSci Advisors | Chief Operating Officer and Chief Financial Officer |
(212) 915-2569 | (858) 771-4193 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-301264794.html
SOURCE Viracta
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.